cardiovascular disease – Page 2

Eli Lilly and Company will acquire private Versanis for $ 1.93 billion in cash to expand its portfolio of obesity drugs, the Indianapolis-based company said in a statement.

Eli Lilly to acquire Versanis for $1.9 billion in an obesity drug push

HQ Team July `4, 2023: Eli Lilly and Company will acquire private Versanis for $ 1.93 billion in cash to expand its portfolio.

by HealthQuill
July 14, 2023
0 Comments

The use of non-sugar sweeteners leads to an increased risk of type 2 diabetes, cardiovascular diseases, and mortality in adults in the long term, according to the World Health Organization.

Drugs Health Pharma

WHO advises against use of non-sugar sweeteners for weight loss, NCDs

HQ Team May 15, 2023: The use of non-sugar sweeteners leads to an increased risk of type 2 diabetes, cardiovascular diseases, and mortality.

by HealthQuill
May 15, 2023
0 Comments

A probe by the US-based Centres for Disease Control into the deaths of 70 children in Gambia "strongly suggests" cough syrups involving contaminated diethylene glycol and ethyl glycol, by an Indian company, were involved.

Health Medical

Eight-fold increased risk of heart attack in patients with undetected coronary condition

Researchers from the University of Copenhagen in Denmark have found asymptomatic people with undetected obstructive coronary atherosclerosis increase their risk for a heart.

by HealthQuill
April 1, 2023
0 Comments

GE Healthcare has pulled out 688 medical systems that evaluate diseases, trauma, abnormalities and disorders, a move which USFDA termed a most severe type of recall.

Drugs Medical Pharma

GE Healthcare recalls 688 medical systems, FDA says ‘most serious’

GE Healthcare has pulled out 688 medical systems that evaluate diseases, trauma, abnormalities and disorders, a move which USFDA termed a most severe.

by HealthQuill
February 16, 2023
0 Comments

Moderna, a US-based biotechnology company, hopeful of cancer vaccine by 2030

Drugs Pharma

Moderna in $35 million licensing deal with CytomX

Moderna, a US-based biotechnology company, announced a $35 million licensing deal with cancer-focused drugmaker CytomX to develop messenger RNA therapies.